CA2929907A1 - Hydrobromide salt of n-(4-chloro-2-hydroxy-3-((3s)-3-piperidinylsulfonyl)phenyl-n'-(3-fluoro-2-methylphenyl)urea - Google Patents

Hydrobromide salt of n-(4-chloro-2-hydroxy-3-((3s)-3-piperidinylsulfonyl)phenyl-n'-(3-fluoro-2-methylphenyl)urea Download PDF

Info

Publication number
CA2929907A1
CA2929907A1 CA2929907A CA2929907A CA2929907A1 CA 2929907 A1 CA2929907 A1 CA 2929907A1 CA 2929907 A CA2929907 A CA 2929907A CA 2929907 A CA2929907 A CA 2929907A CA 2929907 A1 CA2929907 A1 CA 2929907A1
Authority
CA
Canada
Prior art keywords
disease
compound
condition
treating
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2929907A
Other languages
English (en)
French (fr)
Inventor
Francis Dominic Sanderson
Sarah Mary VALLANCE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
Original Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd
Publication of CA2929907A1 publication Critical patent/CA2929907A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
CA2929907A 2013-11-13 2014-11-11 Hydrobromide salt of n-(4-chloro-2-hydroxy-3-((3s)-3-piperidinylsulfonyl)phenyl-n'-(3-fluoro-2-methylphenyl)urea Abandoned CA2929907A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1320021.7 2013-11-13
GBGB1320021.7A GB201320021D0 (en) 2013-11-13 2013-11-13 Novel Compounds
PCT/EP2014/074222 WO2015071235A1 (en) 2013-11-13 2014-11-11 Hydrobromide salt ofn-(4-chloro-2-hydroxy-3-((3s)-3-piperidinylsulfonyl)phenyl-n'-(3-fluoro-2-methylphenyl)urea

Publications (1)

Publication Number Publication Date
CA2929907A1 true CA2929907A1 (en) 2015-05-21

Family

ID=49818555

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2929907A Abandoned CA2929907A1 (en) 2013-11-13 2014-11-11 Hydrobromide salt of n-(4-chloro-2-hydroxy-3-((3s)-3-piperidinylsulfonyl)phenyl-n'-(3-fluoro-2-methylphenyl)urea

Country Status (24)

Country Link
US (3) US9809540B2 (https=)
EP (1) EP3068763B1 (https=)
JP (1) JP6401265B2 (https=)
KR (1) KR20160083950A (https=)
CN (1) CN105683162A (https=)
AU (1) AU2014350334B2 (https=)
BR (1) BR112016010409A8 (https=)
CA (1) CA2929907A1 (https=)
CY (1) CY1121581T1 (https=)
DK (1) DK3068763T3 (https=)
ES (1) ES2714721T3 (https=)
GB (1) GB201320021D0 (https=)
HR (1) HRP20190449T1 (https=)
HU (1) HUE041873T2 (https=)
LT (1) LT3068763T (https=)
ME (1) ME03328B (https=)
PL (1) PL3068763T3 (https=)
PT (1) PT3068763T (https=)
RS (1) RS58382B1 (https=)
RU (1) RU2685408C1 (https=)
SI (1) SI3068763T1 (https=)
SM (1) SMT201900156T1 (https=)
TR (1) TR201902981T4 (https=)
WO (1) WO2015071235A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170100385A1 (en) * 2014-05-12 2017-04-13 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions comprising danirixin for treating infectious diseases
BR112018011138A2 (pt) * 2015-11-30 2018-11-21 Glaxosmithkline Intellectual Property (No. formulações para administração intravenosa
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Prognosis of demyelinating diseases patients and treatment thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2009992T3 (pl) * 2006-04-21 2012-11-30 Glaxosmithkline Llc Antagoniści receptora IL-8

Also Published As

Publication number Publication date
TR201902981T4 (tr) 2019-03-21
US20180079722A1 (en) 2018-03-22
RU2685408C1 (ru) 2019-04-18
RS58382B1 (sr) 2019-04-30
RU2016116955A (ru) 2017-12-19
EP3068763A1 (en) 2016-09-21
LT3068763T (lt) 2019-03-12
AU2014350334B2 (en) 2017-08-10
PT3068763T (pt) 2019-03-20
HRP20190449T1 (hr) 2019-04-19
CY1121581T1 (el) 2020-05-29
JP2016537344A (ja) 2016-12-01
US20190112269A1 (en) 2019-04-18
GB201320021D0 (en) 2013-12-25
CN105683162A (zh) 2016-06-15
US9809540B2 (en) 2017-11-07
HUE041873T2 (hu) 2019-05-28
BR112016010409A8 (pt) 2020-04-22
EP3068763B1 (en) 2018-12-19
KR20160083950A (ko) 2016-07-12
SI3068763T1 (sl) 2019-04-30
ME03328B (me) 2019-10-20
US10604485B2 (en) 2020-03-31
DK3068763T3 (en) 2019-03-18
ES2714721T3 (es) 2019-05-29
PL3068763T3 (pl) 2019-05-31
WO2015071235A1 (en) 2015-05-21
SMT201900156T1 (it) 2019-05-10
JP6401265B2 (ja) 2018-10-10
AU2014350334A1 (en) 2016-06-02
US20160264525A1 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
RU2758686C2 (ru) Антагонисты tlr7/8 и их применение
CA2915561C (en) Novel substituted bicyclic compounds as bromodomain inhibitors
JP2021105030A (ja) ニコチンアミドリボシドの結晶形
CA3183081A1 (en) Combination therapy for treatment of cancer
JP7660604B2 (ja) ２，４，６－トリフルオロ－ｎ－［６－（１－メチル－ピペリジン－４－カルボニル）－ピリジン－２－イル］－ベンズアミドヘミコハク酸塩の大規模調製のためのプロセスおよび中間体、ならびに２，４，６－トリフルオロ－ｎ－［６－（１－メチル－ピペリジン－４－カルボニル）－ピリジン－２－イル］－ベンズアミド酢酸塩の調製
HUE034347T2 (en) N-heteroaryl compounds with a cyclic bridge unit for the treatment of parasitic diseases
TW200927129A (en) Organic compounds
US10604485B2 (en) Hydrobromide salt of N-(4-chloro-2-hydroxy-3-((3S)-3-piperidinylsulfonyl)phenyl-N′-(3-Fluoro-2-methylphenyl)urea
TR201802206T4 (tr) Amorf (5-Floro-2-metil-3-kinolin-2-ilmetil-indol-1-il)-asetik asit.
CA3075705A1 (en) Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia
CN109415339A (zh) N-[2-(3-羟基-3-甲基丁基)-6-(2-羟基丙-2-基)-2h-吲唑-5-基]-6-(三氟甲基)吡啶-2-甲酰胺的结晶形式
TW200526573A (en) Organic compounds
JP2025510813A (ja) Ｔｙｋ２阻害剤及びその使用
JP2025507623A (ja) （ｓ）－１－（（２’，６－ビス（ジフルオロメチル）－［２，４’－ビピリジン］－５－イル）オキシ）－２，４－ジメチルペンタン－２－アミン及びその塩の固体形態
WO2017106872A1 (en) Alkynyl dihydroquinoline sulfonamide compounds
TW202340182A (zh) 做為ｒｉｐｋ１抑制劑之異㗁唑啶及其用途
CN111620815B (zh) 手性氯喹、羟氯喹和其衍生物及其制备方法与用途
CN112839656A (zh) 急性骨髓性白血病用抗肿瘤剂
JPH09511483A (ja) α−２−アドレノセプター作動剤として有用な６−（２−イミダゾリニルアミノ）キノリン化合物
EP3999056B1 (en) Pharmaceutical combination and its use in the prevention and treatment of cancer
HUE028761T2 (en) Crystalline form of a succinate salt
JP2011246478A (ja) テルカゲパントカリウムの固形投与製剤
JP2022532186A (ja) 非晶質のｐｉ３ｋ阻害剤及びこれを含有する医薬組成物
RU2161967C2 (ru) Соединения 7-(2-имидазолиниламино) хинолина, пригодные в качестве агонистов альфа-2-адренорецептора
WO2018186775A1 (ru) Соли 4-((2-(6-(4-метилпиперазин-1-карбонил)нафталин-2-ил)этил)амино)хиназолин-6-карбонитрила и фармацевтическая композиция

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20221206